MDXH PE Ratio & Valuation, Is MDXH Overvalued

Historical Valuation

MDxHealth SA (MDXH) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.84 is considered Undervalued compared with the five-year average of 0.06. The fair price of MDxHealth SA (MDXH) is between 54.55 to 57.99 according to relative valuation method. Compared to the current price of 2.16 USD , MDxHealth SA By Undervalued By 96.04%.

Relative Value

Fair Zone

54.55-57.99

Current Price：2.16

96.04%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is MDxHealth SA (MDXH) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

MDxHealth SA (MDXH) has a current Price-to-Book (P/B) ratio of -9.77. Compared to its 3-year average P/B ratio of -26.55, the current P/B ratio is approximately -63.20% higher. Relative to its 5-year average P/B ratio of -25.14, the current P/B ratio is about -61.14% higher. MDxHealth SA (MDXH) has a Forward Free Cash Flow (FCF) yield of approximately -11.24%. Compared to its 3-year average FCF yield of -20.71%, the current FCF yield is approximately -45.70% lower. Relative to its 5-year average FCF yield of -89791.28%, the current FCF yield is about -99.99% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for MDXH competitors is 90.85, providing a benchmark for relative valuation. MDxHealth SA Corp (MDXH.O) exhibits a P/S ratio of 0.82, which is -99.1% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of MDXH increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of MDXH in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is MDXH currently overvalued or undervalued?

What is MDxHealth SA (MDXH) fair value?

MDXH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of MDxHealth SA (MDXH) is between 54.55 to 57.99 according to relative valuation method.

How does MDXH's valuation metrics compare to the industry average?

The average P/S ratio for MDXH's competitors is 90.85, providing a benchmark for relative valuation. MDxHealth SA Corp (MDXH) exhibits a P/S ratio of 0.82, which is -99.10% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for MDxHealth SA (MDXH) as of Apr 03 2026?

As of Apr 03 2026, MDxHealth SA (MDXH) has a P/B ratio of -9.77. This indicates that the market values MDXH at -9.77 times its book value.

What is the current FCF Yield for MDxHealth SA (MDXH) as of Apr 03 2026?

As of Apr 03 2026, MDxHealth SA (MDXH) has a FCF Yield of -11.24%. This means that for every dollar of MDxHealth SA's market capitalization, the company generates -11.24 cents in free cash flow.

What is the current Forward P/E ratio for MDxHealth SA (MDXH) as of Apr 03 2026?

As of Apr 03 2026, MDxHealth SA (MDXH) has a Forward P/E ratio of 27.70. This means the market is willing to pay $27.70 for every dollar of MDxHealth SA's expected earnings over the next 12 months.

What is the current Forward P/S ratio for MDxHealth SA (MDXH) as of Apr 03 2026?

As of Apr 03 2026, MDxHealth SA (MDXH) has a Forward P/S ratio of 0.84. This means the market is valuing MDXH at $0.84 for every dollar of expected revenue over the next 12 months.

MDXH Valuation